Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: Results from a multi-ethnic New Zealand cohort

Lupus

Volumn 16, Issue 10, 2007, Pages 830-837

  Burling, Fraser ^a,b,d   Ng, J ^a   Thein, H ^a   Ly, J ^c   Marshall, M R ^a   Gow, P ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b Rheumatology and Musculo Skeletal Clinic   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d NONE   (New Zealand)

Author keywords

Anaemia; dsDNA; Lupus nephritis; Maori; Systemic lupus erythematosis

Indexed keywords

DOUBLE STRANDED DNA;

ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ETHNIC GROUP; FEMALE; HUMAN; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANEMIA; AUTOIMMUNITY; COHORT STUDIES; COMPLEMENT SYSTEM PROTEINS; DNA; ETHNIC GROUPS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; NEW ZEALAND; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 35948953290     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307080225     Document Type: Article

References (60)

1. Kewalramani R, Singh AK. Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr Opin Nephrol Hypertens 2002; 11: 273-277.
2. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary and haematologic disease. Ann Intern Med 1995; 122: 940-950.
3. Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. Current Opinion Rheumatol 2002; 14: 498-503.
4. Lee PT, Fang HC, Chen CL, Chiou YH, Chou KJ, Chung HM. Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus 2003; 12: 827-832.
5. Bujan S, Ordi-Ros J, Paredes J et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 2003; 62: 859-865.
6. Cortes-Hernandez J, Ordi-Ros J, Labrador M et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296.
7. Koffler D, Agnello V, Thoburn R, Kunkel HG. SLE, prototype of immune complex nephritis in man. J Exp Med 1971; 134(Suppl): 169s-179s.
8. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4: 1499-1515.
9. Hochberg MC, Petri M. Clinical features of systemic lupus erythematosus. Current Opin Rheum 1993; 5: 575-586.
10. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996; 39: 894-903.
11. Lewis EJ, Schwartz MM. Pathology of lupus nephritis. Lupus 2005; 14: 31-38.
12. Waldman M, Madaio MPP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005; 14: 19-24.
13. Zimmerman R, Radhakrishnan J, Baleri A, Appel G. Advances in the treatment of lupus nephritis. Ann Rev Med 2001; 52: 63-78.
14. Rekvig OP, Kalaaji M, Nossent H. Anti-DNA antibody subpopulations and lupus nephritis. Autoimmunity Reviews 2004; 3: 1-6.
15. Wallace DJ. Dubois, lupus erythematosus. In Wallace, DJ, Hahn, BH eds. The clinical presentation of systemic lupus erythematosus. Williams and Wilkins, 1996; 627.
16. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
17. Arbuckle MR, James JA, Dennis GJ et al. Rapid progression to diagnosis among African-American men with systemic lupus erythematosus. Lupus 2003; 12: 99-106.
18. Massardo L, Martinez ME, Jacobelli S, Villarroel L, Rosenberg H, Rivero S. Survival of Chilean patients with systemic lupus erythematosus. Arthritis & Rheum 1994; 24: 1-11.
19. Al Attia HM, Al Ahmed YH, Chandani AU. Serological markers in Arabs with lupus nephritis. Lupus 1998; 7: 198-201.
20. Mok CC, Tang SSK. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 2004; 117: 791-795.
21. Mok CC, Lau CS, Chan TM, Wong RWS. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus 1999; 8: 188-196.
22. Hopkinson ND, Jenkinson C, Muir KR, Doherty M, Powell RJ. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 116-119.
23. Toloza SMA, Roseman JM, Alarcon GS et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). Arthritis & Rheum 2004; 50: 3177-3186.
24. Li Thi Huong D, Papo T, Beaufils H et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine 1999; 78: 148-166.
25. Marto N, Bertolaccini ML, Calabuig E, Hughes GRV, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444-448.
26. Bastian HM, Roseman JM, McGwin Jr G et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. (LUMINA Study Group). Lupus 2002; 11: 152-160.
27. Sasaki T, Muryoi T, Hatakeyama A et al. Circulating anti-DNA immune complexes in active lupus nephritis. Am J Med 1991; 91: 355-362.
28. Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus. Rheumatology 2001; 40: 1405-1412.
29. Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004; 13: 36-44.
30. Naiker IP, Rughubar KN, Duursma J, Pudifin DJ, Seedat YK. Anticardiolipin antibodies in South African patients with lupus nephritis: a clinical and renal pathological study. Am J Nephrol 2000; 20: 351-357.
31. Loizou S, Samarkos M, Norsworthy PJ, Cazabon JK, Walport MJ, Davies KA. Significance of anticardiolipin and anti-B2-glycoprotein I antibodies in lupus nephritis. Rheumatology 2000; 39: 962-968.
32. Font J, Cervera R, Ramos-Casals M et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Seminars in Arthritis and Rheumatism 2004; 33: 217-230.
33. Daugas E, Nochy D, Huong DLT et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 42-52.
34. Migliorini P, Baldini C, Rocchi V, Bombadieri S. Anti-Sm and Anti-RNP antibodies. Autoimmunity 2005; 38: 47-54.
35. Fremeaux-Bacchi V, Noel LH, Schifferli JA. No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol Dial Transplant 2002; 17: 2041-2043.
36. Porcel JM, Ordi J, Castro-Salomo A et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol and Immunopath 1995; 74: 283-288.
37. Williams W, Shah D, Sargeant LA. The clinical and epidemiologic features in 140 patients with lupus nephritis in a predominantly black population from one center in Kingston, Jamaica. Am J Med Sci 2004; 327: 324-329.
38. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082-2088.
39. Barr RG, Seliger S, Appel GB et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrology Dialysis Transplantation 2003; 18: 2039-2046.
40. Wada Y, Satoshi I, Ueno M et al. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004; 98: c105-c111.
41. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of the systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
42. Hochburg MC. Updating the American College of Rheumatology revisited criteria for the classification of SLE. Arthritis Rheum 1997; 40: 1725.
43. Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus 2005; 14: 25-30.
44. Vila LM, Alarcon GS, Mc Gwin Jr G et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheum 2005; 32: 2150-2155.
45. Witte T, Hartung K, Sachse S et al. IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. Rheumatol Int 1998; 18: 85-91.
46. Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus erythematosus. Ann Rheum Dis 1983; 42: 529-532.
47. Petri M, Perez-Gutthanns S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: Tole of race and socio-economic status. Am J Med 1991; 91: 345-353.
48. McAlindon T, Gianotta L, Taub N, D'Cruz D, Hughes G. Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 720-724.
49. Studenski S, Allen N, Caldwell D, Rice J, Polisson R. Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors. Arthritis Rheum 1987; 30: 1326-1332.
50. Dooely MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188-1195.
51. Ward M, Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socio-economic factors. Arch Intern Med 1990; 150: 849-853.
52. Mok CC. Prognostic factors in lupus nephritis. Lupus 2005; 14: 39-44.
53. Thompson CF, Simmons D, Collins JF et al. Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus. Diabet Med 2001; 18: 40-46.
54. Adler S. Renal disease: environment, race, or genes? Ethn Dis 2006; 16(Suppl 2): 35-39.
55. Kyle CV, Abbott W, Young RP et al. Angiotensin-1-converting enzyme and angiotensinogen gene polymorphisms in Maori and Pacific Island people in New Zealand. Intern Med J 2001; 31: 116-118.
56. Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772.
57. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of non-traditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17.
58. Barnes EV, Narain S, Naranjo A et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576-582.
59. Williams RC Jr, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 2005; 32: 454-461.
60. Wais T, Fierz W, Stoll T, Villiger PM. Subclinical disease activity in systemic lupus erythematosus: immuno-inflammatory markers do not normalize in clinical remission. J Rheumatol 2003; 30: 2133-2139.